ABPWW — Abpro Holdings, Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1893219 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,175,000 | -940,000 | 5,241,000 | 4,236,000 | 8,225,000 |
| Mar 2026 | 0 | — | -933,000 | -1,028,000 | 6,865,000 | 5,398,000 | 9,117,000 |
| Dec 2025 | 0 | — | 2,504,000 | 5,636,000 | 1,063,000 | 67,000 | 9,345,000 |
| Sep 2025 | 0 | — | -1,336,000 | -1,657,000 | 1,703,000 | 328,000 | 17,298,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,583,000
Investing CF
$-29,638,990
Financing CF
$10,565,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-120,023,000
Inventory
—
Receivables
$183,000
ST Investments
—
EBIT TTM
$1,481,000
Pretax Income TTM
$-33,000
Interest Exp TTM
$1,514,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -4,051,000 | -2,892,000 | 1,063,000 | 9,345,000 | -8,831,000 | -6,006,000 |
| Dec 2024 | 183,000 | -9,921,000 | -7,232,000 | 4,661,000 | 19,607,000 | -15,495,000 | -9,030,000 |
| Dec 2023 | 122,000 | -11,746,000 | -11,706,000 | 3,355,000 | 91,790,000 | -88,984,000 | -7,402,000 |
| Dec 2022 | 2,029,000 | -16,685,000 | -17,215,000 | 11,852,000 | 87,586,000 | -76,283,000 | -8,952,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $224.15B | $414.61 | — |
| GILD | GILEAD SCIENCES, INC. | $187.15B | $150.93 | — |
| MRNA | Moderna, Inc. | $79.40B | $198.88 | — |
| ARGX | ARGENX SE | $59.67B | $959.49 | — |
| RVMD | Revolution Medicines, Inc. | $43.93B | $204.97 | — |
News headlines (Yahoo Finance, 1h cache)
Delisting of Securities from The Nasdaq Stock Market
2026-09-17 13:00 · Yahoo
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
2026-01-06 12:00 · Yahoo
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
2025-12-15 12:00 · Yahoo
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
2025-11-03 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.